Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
14 Total results for product and free and sample content found
Datamonitor Healthcare
By Colin White, Robert Jeng & Jolene Lau 19 Sep 2017
This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well
Topic immuno-oncology
Datamonitor Healthcare
By Dustin Phan 18 Sep 2017
Recently, Informa Pharma Intelligence conduced an insightful webinar regarding the current market landscape and outlook for immuno-oncology.
Topic immuno-oncology
Scrip
By Lubna Ahmed 03 Aug 2017
The US FDA has approved BMS' Opdivo for previously treated patients with some forms of colorectal cancer, however direct competition from Merck's Keytruda may limit its success.
Topic immuno-oncology Cancer
Scrip
By Lucie Ellis 27 Jul 2017
Leading immunotherapy agents are beginning to report early-stage data from monotherapy and combination trials in advanced cervical cancer – a treatment area with very few approved options.
Scrip
25 Jul 2017
As PD-1 inhibitors march toward earlier-stage head and neck cancers, researchers consider ways to improve the precision of immunotherapy through better patient selection and combinations for this accessible tumor type.
Topic Cancer immuno-oncology
Scrip
By Joseph Haas 05 Jul 2017
Trying to catch up with peers in both immuno-oncology and NASH, the German pharma has assigned Sapountzis to lead its US business development efforts.
Topic Cancer immuno-oncology
Pink Sheet
By Francesca Bruce 07 Jun 2017
The clinical potential of immuno-oncology drugs does not seem to be reflected in approaches by health technology assessment bodies, with different interpretations of data.
Topic immuno-oncology
Scrip
By Joseph Haas 13 Feb 2017
New cancer immunotherapies are doing well in lung cancer, with Merck's Keytruda picking up share in the first-line setting and Roche's Tecentriq in second-line. Bristol-Myers Squibb is banking on combo therapy to restore its momentum.
Topic immuno-oncology
Scrip
By Emily Hayes 03 Feb 2017
Merck's filings in bladder cancer span first-line and second-line treatment and include overall survival data. Roche also is getting ready to move Tecentriq to the frontline setting.
No Records Found
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Report store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
